Southwest Investment Fund backs Green Park Pharma to advance liquid medicines

Green Park Pharma has secured £500,000 in equity funding from the British Business Bank's South West Investment Fund, via appointed Fund Manager, The FSE Group, as part of a £2.2 million pre-Series. A funding round with the option for a further £4.5 million investment in later rounds. This support will help accelerate the development of innovative liquid medicines designed for patients who struggle to swallow tablets.

Tackling an overlooked patient need

An estimated 20–40% of patients worldwide experience difficulty swallowing tablets, including many children and adults living with conditions such as stroke, dementia and some cancers. Today, workarounds often rely on pharmacists reconstituting medicines from powder, producing liquids with short shelf lives that may require refrigeration. Green Park Pharma's innovative approach transforms existing solid medicines into stable, room-temperature liquid formulations with a long shelf life. Unlike traditional pharmacy-prepared liquids, these are or will be fully licensed products designed to improve adherence, dosing accuracy and convenience for the NHS, patients and caregivers.

"Difficulty taking tablets is a common problem in paediatrics but extends to adults experiencing swallow impairment, including those suffering from serious conditions such as stroke, dementia and some forms of cancer," said Richard Reavley, Founder and Group CEO of Green Park Pharma. "Our liquid products are effective and stable at room temperature with a long shelf life, improving medication adherence, dosage accuracy and convenience for the NHS, patients and caregivers. We are thrilled to receive this investment, which will help us make a significant impact on the global pharmaceutical landscape."

Backing growth in the South West

The new investment will enable Green Park Pharma to expand its operations and create up to ten new roles in Newquay over the next three years. This growth will support the company's plans to scale its pipeline of liquid medicines and extend its reach across the UK and international markets.

Anna Staevska, Investment Manager at The FSE Group, commented: "Green Park Pharma's robust business model and innovative approach present a unique opportunity that we're excited to be a part of. The secured funding positions the company well for rapid development and market penetration."

The South West Investment Fund was created to drive sustainable economic growth and increase access to finance for ambitious businesses across the region. Paul Jones, Senior Investment Manager at British Business Bank, noted: "Green Park Pharma is an excellent example of an innovative, high-growth business that the South West Investment Fund was created to support."

A platform for partnership

Green Park Pharma is led by an experienced team with a track record of launching more than 40 pharmaceutical products globally. By combining advanced liquid formulation technology with deep commercial and regulatory expertise, the company is well-positioned to collaborate with partners seeking to bring patient-friendly medicines to more people, more quickly.

Interested in partnering with Green Park Pharma?

Contact us to discuss in-licensing opportunities into the UK and Europe or explore collaboration on patient-centric liquid formulations.